Previous 10 | Next 10 |
UK-based Allergy Therapeutics ( OTCPK:AGYTF ) announces the publication of positive data on its peanut allergy vaccine candidate in The Journal of Allergy and Clinical Immunology. More news on: Allergy Therapeutics plc, Aimmune Therapeutics, Inc., DBV Technologies S.A., Healthcare sto...
Aimmune Therapeutics, Inc. ( AIMT ) has risen more than 80% since early September (from under $20 to near $34 now) in anticipation of the FDA approval of Palfrozia – previously known as AR-101 – as the first ever approved treatment for children who suffer from peanut allergies. B...
AMF REGULATED INFORMATION Montrouge, France, January 15, 2020 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today ...
Apellis Pharmaceuticals ( APLS ) reported positive results from a Phase 3 clinical trial, PEGASUS , evaluating pegcetacoplan (APL-2) in adults with paroxysmal nocturnal hemoglobinuria. The trial pitted the drug directly against Alexion's Soliris and offered positive results. As per the resu...
Aimmune Therapeutics ' (NASDAQ: AIMT) share price has gained 11% over the past month as the company waits for the Food and Drug Administration to issue an approval decision on its very first drug, one that represents the theme of its three-drug pipeline: treatments to address food allerg...
Shares of DBV Technologies (NASDAQ: DBVT) are up 11% at 12:40 p.m. EST on positive long-term data for the biotech 's peanut allergy medication Viaskin Peanut. Children in the phase 3 Pepites clinical trial were able to continue on the drug in an extension study called People. After three y...
Applied Genetic Technologies (NASDAQ: AGTC ) +53% on positive XLRP data . More news on: Applied Genetic Technologies Corporation, VBI Vaccines Inc., The Peck Company Holdings, Inc., Stocks on the move, Read more ...
Aptose Biosciences (APS CN) initiated with Overweight rating at Piper Sandler. Shares up 2% premarket in U.S. (NASDAQ: APTO ). More news on: Aptose Biosciences Inc., BioDelivery Sciences International, Inc., BiomX Inc., Healthcare stocks news, Stocks on the move, , Read mor...
Gainers: CHS +26.9% . DBVT +21.6% . AGTC +13.9% . NNVC +10.3% . OTCQX:AKOM +9.1% . More news on: Chico's FAS, Inc., DBV Technologies S.A., Applied Genetic Technologies Corporation, Stocks on the move, , News on ETFs Read more ...
DBV Technologies (NASDAQ: DBVT ) announces positive long-term results from the open-label extension study (( PEOPLE )) of its Phase 3 clinical trial, PEPITES , evaluating Viaskin Peanut in peanut-allergic children aged 4 - 11 years. More news on: DBV Technologies S.A., Healthcare stocks...
News, Short Squeeze, Breakout and More Instantly...
DBV Technologies S.A. Company Name:
DBVT Stock Symbol:
NASDAQ Market:
DBV Technologies S.A. Website:
Châtillon, France, July 30, 2024 DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutic...
Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expecte...
Châtillon, France, July 29, 2024 DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, toda...